| 4.8 -0.19 (-3.81%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.38 | 1-year : | 7.46 |
| Resists | First : | 5.46 | Second : | 6.38 |
| Pivot price | 4.84  |
|||
| Supports | First : | 4.17 |
Second : | 3.38 |
| MAs | MA(5) : | 4.98  |
MA(20) : | 4.72 |
| MA(100) : | 3.16 |
MA(250) : | 2.56 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 60.4 |
D(3) : | 66.6 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 5.46 | Low : | 1.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMMX ] has closed above bottom band by 46.5%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.03 - 5.06 | 5.06 - 5.08 |
| Low: | 4.6 - 4.63 | 4.63 - 4.66 |
| Close: | 4.75 - 4.8 | 4.8 - 4.84 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Thu, 30 Nov 2023
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit - Yahoo Finance
Wed, 29 Nov 2023
Is Immix Biopharma Inc (IMMX) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver
Tue, 28 Nov 2023
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Simply Wall St
Tue, 28 Nov 2023
Should You Buy Immix Biopharma Inc (IMMX) Stock on Tuesday? - InvestorsObserver
Tue, 28 Nov 2023
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' - Yahoo Finance
Fri, 24 Nov 2023
Pleasing Signs As A Number Of Insiders Buy Immix Biopharma Stock - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 53.4 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 243 (K) |
| Shares Short P.Month | 172 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.7 % |
| Return on Equity (ttm) | -78.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -5.22 |
| PEG Ratio | 0 |
| Price to Book value | 4.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|